Skip to main content
EVH
NYSE Trade & Services

Evolent Q3 Revenue Jumps 51% to $725M but Net Loss Widens to $23.6M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$4.56
Mkt Cap
$542.685M
52W Low
$2.095
52W High
$6.89
52W Position info
118% above low
Off High info
34% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

EVH has more than doubled off its 52-week low of $2.095.

Summary

Evolent grew Q3 revenue 51% to $725.4 million on new Performance Suite contracts, but a 93.0% medical expense ratio pushed it to a $23.6 million net loss. Amended credit agreements now permit up to $50 million of 2029 convertible note repurchases.


Key Events · Earnings and Guidance · EVH

  • Q3 Revenue Up 51% to $725.4M

    Revenue rose $245.8 million, or 51.3%, to $725.4 million, driven by $280.1 million of new Performance Suite contract go-lives and expanded oncology services, partly offset by $22.3 million of membership reductions.

  • Net Loss Widens to $23.6M

    Net loss attributable to common shareholders was $23.6 million, or $0.21 per share, versus $26.9 million a year earlier; operating result swung to a $6.2 million loss from $0.9 million of income.

  • Medical Expense Ratio Climbs to 93.0%

    MER rose from 85.0% to 93.0% as claims incurred on the specialty care management solution reached $525.0 million against $564.3 million of Performance Suite revenue; cost of revenue grew 67.7%, faster than revenue.

  • Credit Agreements Amended October 15

    Amendment No. 7 to the First Lien Credit Agreement and Amendment No. 1 to the Second Lien Credit Agreement expand restricted-payment baskets, including repurchases of up to $50 million of 2029 convertible notes through October 15, 2027, funded solely from internally generated cash.


Analysis · EVH · Trade & Services

Revenue growth is real — $280.1 million of new Performance Suite contract go-lives and expanded oncology services drove the 51.3% jump — but the economics are getting thinner, not better. The Medical Expense Ratio climbed to 93.0% from 85.0%, meaning claims costs are eating a larger share of Performance Suite revenue, and cost of revenue rose 67.7% against 51.3% revenue growth. The result is a $6.2 million operating loss versus a small operating profit a year ago. Cash slipped to $148.3 million from $151.9 million at year-end while the claims reserve nearly doubled to $376.1 million, so the balance sheet is carrying more medical-cost risk. Management still says liquidity covers the next twelve months, and the newly amended credit agreements free up capacity to repurchase up to $50 million of the 2029 convertible notes with internally generated cash — a signal they intend to chip away at the $569.3 million convertible stack rather than raise equity.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EVH was trading at $4.56 on NYSE in the Trade & Services sector, with a market capitalization of approximately $542.7M. The 52-week trading range was $2.10 to $6.89. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EVH - Latest Insights

EVH
Nov 05, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $4.47
Real-time Price: $3.78 info
Change: -$0.690 (-15%) info
Market Cap: $441.112M info
EVH
Aug 06, 2026, 8:53 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.89
Real-time Price: $3.78 info
Change: -$0.110 (-3%) info
Market Cap: $441.112M info
EVH
Aug 06, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.72
Real-time Price: $3.78 info
Change: +$0.0599 (+2%) info
Market Cap: $441.112M info
EVH
May 07, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.03
Real-time Price: $3.78 info
Change: -$0.250 (-6%) info
Market Cap: $441.112M info
EVH
Feb 24, 2026, 6:16 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.43
Real-time Price: $3.78 info
Change: +$1.35 (+56%) info
Market Cap: $441.112M info